Safety and Activity of Sorafenib in Addition to Vinflunine in Post‐Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial

LESSONS LEARNED. First trial to report safety and activity of the microtubule inhibitor vinflunine plus the tyrosine kinase inhibitor sorafenib in post‐platinum metastatic urothelial cancer (mUC) patients. A recommended phase II dose was identified for the treatment combination of vinflunine plus so...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncologist
Главные авторы: Shah, Carl‐Henrik, Pappot, Helle, Agerbæk, Mads, Holmsten, Karin, Jäderling, Fredrik, Yachnin, Jeffrey, Grybäck, Per, von der Maase, Hans, Ullén, Anders
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley & Sons, Inc. 2018
Предметы:
Clinical Trial Results
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656519/
https://ncbi.nlm.nih.gov/pubmed/30552156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0795
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы